APP下载

托伐普坦治疗慢性肺源性心脏病合并心力衰竭的临床效果

2021-03-22关芬礼谭志辉杨伟钊

中国医学创新 2021年35期
关键词:心力衰竭安全性心功能

关芬礼 谭志辉 杨伟钊

【摘要】 目的:探討托伐普坦治疗慢性肺源性心脏病(CPHD)合并心力衰竭(HF)的临床效果。方法:选择阳江江华医院心血管内科2020年6月-2021年6月收治的CPHD合并HF患者120例,采用随机数字表法分为对照组与观察组,每组60例。两组入院后均给予对症支持治疗,对照组采用呋塞米片治疗,观察组采用托伐普坦治疗,比较两组治疗结束后临床治疗效果,治疗前后心功能[右心室射血分数(RVEF)、心脏指数(CI)、心排血量(CO)]、血清脑钠肽(BNP)及治疗期间的不良反应发生情况。结果:观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。治疗前,两组RVEF、CI、CO、BNP水平比较,差异均无统计学意义(P>0.05);治疗后,两组RVEF、CI、CO均高于治疗前,BNP均低于治疗前,观察组RVEF、CI、CO均高于对照组,BNP低于对照组,差异均有统计学意义(P<0.05)。观察组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论:托伐普坦治疗CPHD合并HF效果显著,可明显改善患者心功能,减少不良反应,安全性较高,值得临床应用与推广。

【关键词】 托伐普坦 慢性肺源性心脏病 心力衰竭 心功能 安全性

Clinical Effect of Tolvaptan in the Treatment of Chronic Pulmonary Heart Disease Complicated with Heart Failure/GUAN Fenli, TAN Zhihui, YANG Weizhao. //Medical Innovation of China, 2021, 18(35): -129

[Abstract] Objective: To explore the clinical effect of Tolvaptan in the treatment of chronic pulmonary heart disease (CPHD) complicated with heart failure (HF). Method: A total of 120 patients with chronic pulmonary heart disease complicated with heart failure who were admitted to the department of Cardiovascular Medicine of Yangjiang Jianghua Hospital from June 2020 to June 2021 were selected and divided into the control group and the observation group by a random number table, with 60 cases in each group. After admissioned, both groups were given symptomatic and supportive treated. The control group was treated with Furosemide Tablets, and the observation group was treated with Tolvaptan. The clinical therapeutic effect was compared between the two groups after treatment, cardiac function [right ventricular ejection fraction (RVEF), cardiac index (CI), cardiac output (CO)], serum brain natriuretic peptide (BNP) before and after treatment and adverse reactions during treatment were compared. Result: The total effective rate of the observation group was higher than that of the control group, the difference was statistically significant (P<0.05). Before treatment, there were no significant differences in RVEF, CI, CO and BNP between two groups (P>0.05); after treatment, the RVEF, CI, CO of the two groups were higher than those before treatment, BNP were lower than those before treatment, RVEF, CI, CO of the observation group were higher than those of the control group, BNP was lower than that of the control group, the differences were statistically significant (P<0.05). The incidence of adverse reactions in the observation group was lower than that of the control group, the difference was statistically significant (P<0.05). Conclusion: Tolvaptan is effective in the treatment of chronic pulmonary heart disease complicated with heart failure. It can significantly improve patients’ cardiac function, reduce adverse reactions, and has high safety, it is worthy of clinical application and promotion.

[Key words] Tolvaptan Chronic pulmonary heart disease Heart failure Cardiac function Safety

First-author’s address: Yangjiang Jianghua Hospital, Yangjiang 529500, China

doi:10.3969/j.issn.1674-4985.2021.35.031

慢性肺源性心脏病(chronic pulmonary heart disease,CPHD)是常见的呼吸系统疾病,病情多呈渐进性发展,患者肺组织、血管等慢性缺氧病变可导致肺功能、结构重塑与肺动脉高压形成,最終引发右心室扩张、肥大、心力衰竭[1-3]。临床实践中发现,CPHD虽病情多呈渐进性发展,但以急性发作为主,且发作后病情易反复,导致患者心肺功能受到严重损伤[4]。CPHD的临床治疗多以药物为主,既往临床治疗方案多采用利尿剂,主要目的为减轻心脏负荷,但无法避免大量钠离子流失问题,易对肾功能造成损伤,加重二氧化碳潴留等[5-6]。……

登录APP查看全文

猜你喜欢

心力衰竭安全性心功能
两款输液泵的输血安全性评估
新染料可提高电动汽车安全性
心功能如何分级?
中药汤剂联合中药足浴及耳穴压豆治疗慢性心力衰竭的临床观察
冠心病心力衰竭应用美托洛尔联合曲美他嗪治疗的疗效分析
心力衰竭合并室性心律失常的诊断和治疗进展
ApplePay横空出世 安全性遭受质疑 拿什么保护你,我的苹果支付?
中西医结合治疗舒张性心功能不全临床观察
冠状动脉支架置入后左心功能变化
Imagination发布可实现下一代SoC安全性的OmniShield技术